Bone marrow secrets could predict chemo success in leukemia
NCT ID NCT07587944
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is looking at substances in the bone marrow of adults with acute myeloid leukemia (AML) to see if they can predict how well chemotherapy will work. Researchers will measure certain factors in bone marrow samples from 405 newly diagnosed AML patients and compare them to healthy controls. The goal is to find markers that could help guide treatment and overcome drug resistance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward new ways to predict which AML patients will respond to chemotherapy and identify targets for future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings may not apply to all AML patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Medical University Union Hospital
RECRUITINGFuzhou, Fujian, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tailored chemo cocktail outsmart a common leukemia?
- What does a healthy mouth mean for people with disabilities?
- Can new drug cocktails beat back Hard-to-Treat leukemia?
- Can a pill and injection combo beat AML without harsh chemo?
- Can pressurized oxygen boost cord blood transplants?
- Personalized leukemia vaccine aims to outsmart relapse